-
★
Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12
(Hinzugefügt: 06.12.2021 um 13:50 Uhr)
https://investor.lilly.com/news-releases/news-release-details/lillys-bamlanivimab-etesevimab-authorized-first-and-only
-
★
EMA stoppt Prüfung von Coronamedikament
(Hinzugefügt: 04.11.2021 um 08:39 Uhr)
https://www.aerzteblatt.de/nachrichten/128761/EMA-stoppt-Pruefung-von-Coronamedikament
-
★
Bamlanivimab for Prevention of COVID-19
(Hinzugefügt: 06.06.2021 um 17:30 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2780873
-
★
Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities
(Hinzugefügt: 06.06.2021 um 17:30 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2780870
-
★
Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19
(Hinzugefügt: 10.03.2021 um 20:17 Uhr)
https://investor.lilly.com/news-releases/news-release-details/lillys-bamlanivimab-and-etesevimab-together-reduced
-
Omicron sublineage BQ.1.1 resistance to monoclonal antibodies
(Hinzugefügt: 19.11.2022 um 18:38 Uhr)
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00733-2/fulltext
-
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
(Hinzugefügt: 24.06.2022 um 07:52 Uhr)
https://www.nature.com/articles/s41586-022-04980-y
-
SARS-CoV-2 Omicron BA.2.12.1, BA.4, and BA.5 subvariants evolved to extend antibody evasion
(Hinzugefügt: 30.05.2022 um 14:01 Uhr)
https://www.biorxiv.org/content/10.1101/2022.05.26.493517v1.full.pdf
-
Sensitivity of novel SARS-CoV-2 Omicron subvariants, BA.2.11, BA.2.12.1, BA.4 and BA.5 to therapeutic monoclonal antibodies
(Hinzugefügt: 10.05.2022 um 08:38 Uhr)
https://www.biorxiv.org/content/10.1101/2022.05.03.490409v1
-
New Members Of The Omicron Family Of Viruses: BA.2.12.1, BA.4, And BA.5
(Hinzugefügt: 26.04.2022 um 15:23 Uhr)
https://www.forbes.com/sites/williamhaseltine/2022/04/20/new-members-of-the-omicron-family-of-viruses-ba2121-ba4-and-ba5/?sh=60e2f3387ff8
-
Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individual
(Hinzugefügt: 26.04.2022 um 15:06 Uhr)
https://www.medrxiv.org/content/10.1101/2022.04.11.22272784v1
-
Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
(Hinzugefügt: 11.03.2022 um 10:48 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2201933
-
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant
(Hinzugefügt: 17.02.2022 um 06:48 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2119407
-
Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
(Hinzugefügt: 10.01.2022 um 12:40 Uhr)
https://www.biorxiv.org/content/10.1101/2021.12.03.471045v2
-
Reported in vitro Therapeutic Activity
(Hinzugefügt: 18.12.2021 um 15:17 Uhr)
https://opendata.ncats.nih.gov/variant/activity
-
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies
(Hinzugefügt: 18.12.2021 um 13:59 Uhr)
https://www.biorxiv.org/content/10.1101/2021.12.15.472828v1
-
The Omicron variant is highly resistant against antibody-mediated 2 neutralization – implications for control of the COVID-19 pandemic
(Hinzugefügt: 17.12.2021 um 14:16 Uhr)
https://www.biorxiv.org/content/10.1101/2021.12.12.472286v1.full.pdf
-
Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization
(Hinzugefügt: 17.12.2021 um 10:21 Uhr)
https://www.biorxiv.org/content/10.1101/2021.12.14.472630v1.full.pdf
-
Lilly pulls COVID-19 treatment from EU review while U.S. stocks up
(Hinzugefügt: 09.11.2021 um 16:01 Uhr)
https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-withdraws-eu-rolling-review-covid-19-antibodies-2021-11-02/
-
Monoclonal antibodies can prevent COVID-19—but successful vaccines complicate their future
(Hinzugefügt: 03.11.2021 um 12:03 Uhr)
https://www.science.org/content/article/monoclonal-antibodies-can-prevent-covid-19-successful-vaccines-complicate-their-future
-
B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination
(Hinzugefügt: 22.10.2021 um 16:23 Uhr)
https://www.cell.com/cell-reports/fulltext/S2211-1247(21)01289-4
-
Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19
(Hinzugefügt: 19.09.2021 um 14:43 Uhr)
https://investor.lilly.com/news-releases/news-release-details/emergency-use-authorization-lillys-bamlanivimab-and-etesevimab
-
Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19
(Hinzugefügt: 15.09.2021 um 15:29 Uhr)
https://www.jci.org/articles/view/151697
-
Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany
(Hinzugefügt: 20.07.2021 um 10:57 Uhr)
https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(21)00141-1/fulltext
-
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
(Hinzugefügt: 17.07.2021 um 13:28 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2102685
-
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
(Hinzugefügt: 13.07.2021 um 07:00 Uhr)
https://www.nature.com/articles/s41586-021-03777-9
-
SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination
(Hinzugefügt: 30.06.2021 um 14:32 Uhr)
https://www.cell.com/cell-reports/fulltext/S2211-1247(21)00828-7
-
EXCLUSIVE U.S. opens criminal probe into alleged lapses at Eli Lilly plant
(Hinzugefügt: 28.05.2021 um 08:27 Uhr)
https://www.reuters.com/business/legal/exclusive-us-opens-criminal-probe-into-alleged-lapses-eli-lilly-plant-2021-05-27/
-
Impact of bamlanivimab monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with SARS-CoV-2 infection
(Hinzugefügt: 20.05.2021 um 06:23 Uhr)
https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab254/6276906
-
SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination
(Hinzugefügt: 06.05.2021 um 09:13 Uhr)
https://www.biorxiv.org/content/10.1101/2021.05.04.442663v1
-
Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab Alternative monoclonal antibody therapies authorized to treat patients with COVID-19 remain available
(Hinzugefügt: 17.04.2021 um 10:07 Uhr)
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab
-
Pharma With variants spreading, Eli Lilly cuts solo COVID-19 antibody out of its U.S. supply deal
(Hinzugefügt: 14.04.2021 um 07:03 Uhr)
https://www.fiercepharma.com/pharma/eli-lilly-modifies-covid-19-antibody-agreement-u-s-to-focus-therapy-duo
-
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in non-human primates
(Hinzugefügt: 09.04.2021 um 05:54 Uhr)
https://stm.sciencemag.org/content/early/2021/04/05/scitranslmed.abf1906.full
-
Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016
(Hinzugefügt: 06.04.2021 um 06:39 Uhr)
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00071-9
-
US government stops distribution of Eli Lilly Covid-19 antibody treatment due to spread of coronavirus variants
(Hinzugefügt: 26.03.2021 um 20:45 Uhr)
https://edition.cnn.com/2021/03/25/health/variants-eli-lilly-antibody-therapy-distribution-stops/index.html
-
U.S. limits supply of Eli Lilly’s Covid-19 antibody therapy in California, Arizona and Nevada
(Hinzugefügt: 14.03.2021 um 10:22 Uhr)
https://www.cnbc.com/2021/03/12/us-limits-supply-of-eli-lillys-covid-19-antibody-therapy-in-3-states.html
-
Europäische Arzneimittelagentur prüft Antikörpertherapie gegen COVID-19
(Hinzugefügt: 13.03.2021 um 08:04 Uhr)
https://www.aerzteblatt.de/nachrichten/121972/Europaeische-Arzneimittelagentur-prueft-Antikoerpertherapie-gegen-COVID-19
-
Europe begins rolling review of Eli Lilly's antibodies for Covid-19
(Hinzugefügt: 11.03.2021 um 14:27 Uhr)
https://www.theedgemarkets.com/article/europe-begins-rolling-review-eli-lillys-antibodies-covid19
-
Eli Lilly's combo therapy for COVID-19 cuts serious illness and death in large study
(Hinzugefügt: 10.03.2021 um 20:14 Uhr)
https://www.reuters.com/article/us-health-coronavirus-lilly-idUSKBN2B21C0
-
BAMLANIVIMAB GEGEN COVID-19?
(Hinzugefügt: 24.02.2021 um 08:52 Uhr)
https://www.arznei-telegramm.de/html/2021_02/2102403_01.html
-
Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19
(Hinzugefügt: 10.02.2021 um 09:51 Uhr)
https://investor.lilly.com/news-releases/news-release-details/lillys-bamlanivimab-ly-cov555-administered-etesevimab-ly-cov016
-
Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
(Hinzugefügt: 10.02.2021 um 09:51 Uhr)
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19-0
-
https://www.fda.gov/media/143603/download
(Hinzugefügt: 07.02.2021 um 10:18 Uhr)
https://www.fda.gov/media/143603/download
-
SARS-CoV-2: Forscher finden weitere Mutationen für ein Immunescape
(Hinzugefügt: 27.01.2021 um 09:23 Uhr)
https://www.aerzteblatt.de/nachrichten/120542/SARS-CoV-2-Forscher-finden-weitere-Mutationen-fuer-ein-Immunescape
-
New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent
(Hinzugefügt: 26.01.2021 um 12:48 Uhr)
https://investor.lilly.com/news-releases/news-release-details/new-data-show-treatment-lillys-neutralizing-antibodies
-
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
(Hinzugefügt: 26.01.2021 um 09:06 Uhr)
https://science.sciencemag.org/content/early/2021/01/22/science.abf9302.full
-
Monoclonal antibodies can prevent COVID-19—but successful vaccines complicate their future
(Hinzugefügt: 23.01.2021 um 09:11 Uhr)
https://www.sciencemag.org/news/2021/01/monoclonal-antibodies-can-prevent-covid-19-successful-vaccines-complicate-their-future
-
SARS-CoV-2: Antikörper erzielt primärpräventive Wirkung bei Bewohnern und Mitarbeitern von Pflegeheimen
(Hinzugefügt: 23.01.2021 um 09:03 Uhr)
https://www.aerzteblatt.de/nachrichten/120427/SARS-CoV-2-Antikoerper-erzielt-primaerpraeventive-Wirkung-bei-Bewohnern-und-Mitarbeitern-von-Pflegeheimen
-
Monoclonal Antibody Combo Treatment Reduces Viral Load in Mild-to-Moderate COVID
(Hinzugefügt: 22.01.2021 um 09:00 Uhr)
https://www.medscape.com/viewarticle/944488
-
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial
(Hinzugefügt: 22.01.2021 um 08:56 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2775647
-
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents
(Hinzugefügt: 21.01.2021 um 19:21 Uhr)
https://investor.lilly.com/news-releases/news-release-details/lillys-neutralizing-antibody-bamlanivimab-ly-cov555-prevented
-
Fact Sheet for Patients, Parents and Caregivers Emergency Use Authorization (EUA) of Bamlanivimab for Coronavirus Disease 2019 (COVID-19)
(Hinzugefügt: 11.01.2021 um 19:21 Uhr)
https://www.fda.gov/media/143604/download
-
An EUA for Bamlanivimab—A Monoclonal Antibody for COVID-19
(Hinzugefügt: 07.01.2021 um 05:21 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2774326
-
Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs
(Hinzugefügt: 07.01.2021 um 05:13 Uhr)
https://investor.lilly.com/news-releases/news-release-details/lilly-provides-comprehensive-update-progress-sars-cov-2
-
Lilly Statement Regarding NIH’s ACTIV-3 Clinical Trial
(Hinzugefügt: 07.01.2021 um 05:12 Uhr)
https://www.lilly.com/news/stories/statement-activ3-clinical-trial-nih-covid19
-
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
(Hinzugefügt: 07.01.2021 um 05:12 Uhr)
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2029849?articleTools=true
-
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
(Hinzugefügt: 07.01.2021 um 05:12 Uhr)
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2033130?articleTools=true